Formosa Pharmaceuticals is a Taiwan-based biotechnology firm with global alliances in US and Asia.
Formosa Pharmaceuticals' proprietary nanoparticle reduction drug-delivery technology (APNT™) improves the dissolution and bioavailability of poorly-soluble APIs via the primary principle of particle size reduction. APP13007, developed through APNT™, has completed a complete battery of clinical trials the United States for inflammation and pain after cataract surgery and is in preparation for NDA submission this year. In June, 2021, we licensed APP13007 to China Grand Pharmaceutical and Healthcare Holdings, Ltd. for the territory including Mainland China, Hong Kong, and Macau. We welcome additional inquiries for other regional licensing for APP13007, as well as co-development opportunities applying APNT™ to small-molecule drug candidates which suffer from poor pharmacokinetics and bioavailability.
TSY-0110, our ADC biosimilar of Kadcyla, is in late preclinical development and is another key objective during our BIO conference attendance. In collaboration with EirGenix, key supplier of the trastuzumab intermediate, we manufacture drug substance and drug product in-house. We are pleased to explore co-development or licensing opportunities both regionally and globally.
Formosa Pharmaceuticals' proprietary nanoparticle reduction drug-delivery technology (APNT™) improves the dissolution and bioavailability of poorly-soluble APIs via the primary principle of particle size reduction. APP13007, developed through APNT™, has completed a complete battery of clinical trials the United States for inflammation and pain after cataract surgery and is in preparation for NDA submission this year. In June, 2021, we licensed APP13007 to China Grand Pharmaceutical and Healthcare Holdings, Ltd. for the territory including Mainland China, Hong Kong, and Macau. We welcome additional inquiries for other regional licensing for APP13007, as well as co-development opportunities applying APNT™ to small-molecule drug candidates which suffer from poor pharmacokinetics and bioavailability.
TSY-0110, our ADC biosimilar of Kadcyla, is in late preclinical development and is another key objective during our BIO conference attendance. In collaboration with EirGenix, key supplier of the trastuzumab intermediate, we manufacture drug substance and drug product in-house. We are pleased to explore co-development or licensing opportunities both regionally and globally.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
